Tests HS-20137 in adults with moderate-to-severe plaque psoriasis

Trial details

Who runs it

Hansoh BioMedical R&D Company

Trial code

NCT07879885

Record updated

20 October 2026

Original description

The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasisRead full original descriptionShow less

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants With Moderate-to-severe Plaque Psoriasis

The purpose of this study is to evaluate the safety and efficacy of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

Inclusion: Adults aged 18 and above, male or female; Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis; During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥3%; b) PASI≥3; Voluntarily participate in the research, have the ability and willingness to complete the research according to the research protocol, and sign the informed consent.

Exclusion: History of an allergic reaction following prior use of a biologic agent, allergy to known drug components, or a history of severe food or drug allergy; Primary treatment failure occurred with previous use of similar investigatory drugs (including marketed ulinumab, gusecciumab, Tiricizumab, Lisenciumab, and IL-23 target investigatory drugs under development) (the minimum treatment standard was not reached 12 weeks after the first treatment); A history of chronic recurrent infection, or opportunistic infection in the 6 months prior to screening, or hospitalization for a serious infectious disease or intravenous antibiotic use in the 2 months prior to randomization, with a confirmed or suspected illness in the 1 week prior to the first dose. And Other circumstances determined by the investigator to be unsuitable for further study participation; Other skin lesions, chronic inflammatory diseases or autoimmune diseases, including but not limited to systemic lupus erythematosus, Sjogren's syndrome, skin sclerosis, etc., assessed by the investigator and other factors that may affect the efficacy evaluation or assessed by other researchers before the first dose; Confirmation of other types of psoriasis, including but not limited to guttiform psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced exacerbation of psoriasis (including beta-blockers, non-steroidal anti-inflammatory drugs, antimalarial drugs, interferon, calcium channel blockers, or lithium induced psoriasis) from the screening period to the time before the first dose; Use of the following drugs before the first dose:; Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before the first dose; 1 weeks before the first administration, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis; Prior to the first dose, use of other biologics for the treatment of psoriasis (including but not limited to TNF α inhibitors, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, and investigational IL 23 targeting drugs) without meeting the protocol required time interval for re administration of the original biologic; use of lymphocyte migration regulators or B cell and T cell regulators (including but not limited to abatacept, telitacicept, etc.), within 3 months before dose, or 6 months before screening, (whichever is older) use of B-cell-specific scavenging drugs (including but not limited to rituximab, inebilizumab, etc.).

ClinicalTrials.gov NCT07879885